LNSR
What one share of Lensar holds
Surgical and Medical Instruments and Apparatus
We are a commercial-stage medical device company focused on designing, developing and marketing advanced laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism.
Lensar’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.34 |
|---|---|
| Profit | $0.81 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.41 |
| Cash and investments | $1.10 |
| Debt | $0.31 |
| Book value | $1.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $28.53 | −$13.70 | $0.36 | −$12.13 | — | −$28.55 |
| 2020 | $5.71 | −$4.28 | $0.08 | −$3.06 | — | — |
| 2021 | $3.68 | −$2.09 | $0.04 | −$0.99 | — | $4.99 |
| 2022 | $3.48 | −$1.96 | $0.01 | −$1.47 | — | $3.78 |
| 2023 | $3.84 | −$1.31 | $0.02 | −$0.90 | — | $2.95 |
| 2024 | $4.64 | −$2.73 | $0.01 | −$0.21 | — | $0.42 |
| 2025 | $4.89 | −$2.87 | $0.01 | −$1.25 | — | −$2.17 |